Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Nicole C. Solomon"'
Autor:
Brian Mac Grory, Ying Xian, Nicole C. Solomon, Roland A. Matsouaka, Marquita R. Decker‐Palmer, Gregg C. Fonarow, Eric E. Smith, Lee H. Schwamm
Publikováno v:
Stroke: Vascular and Interventional Neurology, Vol 2, Iss 1 (2022)
Background Early administration of intravenous tissue plasminogen activator (IV alteplase) improves functional outcomes in patients with acute ischemic stroke, yet many patients are not treated with IV alteplase. There is a need to understand the rea
Externí odkaz:
https://doaj.org/article/e9cfe2efad914c49998da64e89dfcc84
Autor:
Halabi S; Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY. susan.halabi@duke.edu., Kelly WK; Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY., Ma H; Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY., Zhou H; Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY., Solomon NC; Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY., Fizazi K; Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY., Tangen CM; Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY., Rosenthal M; Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY., Petrylak DP; Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY., Hussain M; Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY., Vogelzang NJ; Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY., Thompson IM; Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY., Chi KN; Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY., de Bono J; Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY., Armstrong AJ; Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY., Eisenberger MA; Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY., Fandi A; Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY., Li S; Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY., Araujo JC; Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY., Logothetis CJ; Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY., Quinn DI; Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY., Morris MJ; Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY., Higano CS; Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY., Tannock IF; Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY., Small EJ; Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2016 May 10; Vol. 34 (14), pp. 1652-9. Date of Electronic Publication: 2016 Mar 07.
Autor:
Halabi S; Susan Halabi, Andrew J. Armstrong, Ellen Kaplan, Chen-Yen Lin, and Nicole C. Solomon, Duke University, Durham, NC; Oliver Sartor, Tulane University, New Orleans, LA; Johann de Bono, Royal Marsden Hospital, Sutton, United Kingdom; and Eric J. Small, University of California at San Francisco, San Francisco, CA., Armstrong AJ, Sartor O, de Bono J, Kaplan E, Lin CY, Solomon NC, Small EJ
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2013 Nov 01; Vol. 31 (31), pp. 3944-50. Date of Electronic Publication: 2013 Oct 07.